Autologous and Allogeneic Transplant for Relapsed Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2014

Study Completion Date

October 22, 2014

Conditions
Non-Hodgkin's LymphomaHodgkins Disease
Interventions
DRUG

Fludarabine

Fludarabine 30 mg/m2 x 5 days

DRUG

Busulfan

Busulfan 3.2 mg/kg/day x 2 days

DRUG

Anti-Thymocyte Globulin

Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days

Trial Locations (6)

10032

Columbia University Medical Center, New York

10595

New York Medical College, Valhalla

27708

Duke University, Durham

53226

Medical College of Wisconsin, Milwaukee

60611

Children's Memorial Hospital in Chicago, Chicago

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Columbia University

OTHER

NCT00802113 - Autologous and Allogeneic Transplant for Relapsed Lymphoma | Biotech Hunter | Biotech Hunter